Cancer Equity From Patient Advocates Financial toxicity, lack of information dissemination, and historical instances of medical mistrust threaten underserved communities’ ability and willingness to participate in cancer prevention, routine cancer
Search Results
James McCanney, Terrell Johnson, Lindsey A.M. Bandini, Shonta Chambers, Lynette Bonar, and Robert W. Carlson
just how widespread the current platinum chemotherapy shortage is, and shared a statement calling on the whole oncology community to work together on solutions. “This is an unacceptable situation. We are hearing from oncologists and pharmacists
David C. Hohn
advocate of health services research, was deeply concerned about discordant patterns of cancer care in both academic and community cancer centers in the face of compelling evidence from clinical trials. Dr. Winn felt strongly that the best strategy for
Joseph V. Simone
of all kinds because one of the provisions in the draft proposal was to redirect patients to community hospitals, which were far less expensive than academic hospitals. I had been at Memorial Sloan Kettering Cancer Center for only a year and became
Rodger J. Winn
enrollment . J Clin Oncol 2001 ; 19 : 1728 – 1733 . 12 Winn RJ . Obstacles to the accrual of patients to clinical trials in the community setting . Semin Oncol 1994 ; 21 ( Suppl 7 ): 112 – 117 . 13 Comis RLl Miller JD Aldige CR
Elizabeth Danielson and Patricia J. Goldsmith
health plans and health insurance companies should be looking for value for their premium dollars, not only lower costs. Most cancer care can be obtained in the community, but an estimated 10% to 15% of cancer patients should have the option of treatment
Carmen P. Escalante, Ellen Manzullo, and Rosalie Valdres
: results from a prospective community oncology study . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 5 Glaus A Crow R Hammond S . A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals
Shawna L. Ehlers
conduct of clinical trials. We can further challenge ourselves as a comprehensive cancer care community by asking “How do I expand prognostic modeling within my own work?” Some thoughts on this are below: Existing knowledge: What are the prognostic
receive monoclonal antibodies for protection.” NCCN’s recommendations point out that vaccine hesitancy in the general population impedes the development of herd (community) immunity, which leaves people with cancer at higher risk. Reducing community
was a year of reckoning with the United States’ history of racial inequity, in which NCCN and the greater healthcare community have been called with renewed urgency to develop ways to make quality cancer care more accessible and equitable